NCT06698809View on ClinicalTrials.gov

Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness

NANot yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

October 25, 2025

Study Completion Date

December 1, 2025

Conditions
Obstructive Sleep ApneaSleepiness
Interventions
DEVICE

Active tPBM

tPBM is a neuromodulatory treatment that uses red and/or near infrared light to penetrate the cortex and can alter both cerebral metabolism and blood flow. Subjects will receive treatment for approximately 12 minutes per treatment.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
collaborator

American Academy of Sleep Medicine

OTHER

lead

NYU Langone Health

OTHER

NCT06698809 - Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness | Biotech Hunter | Biotech Hunter